

**PATENT APPLICATION**  
Attorney Docket No. 15966-546CON-S22

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS :               Fernandes  
SERIAL NUMBER :       Not Yet Assigned                               EXAMINER :       Not Yet Assigned  
FILING DATE :           Herewith                                       ART UNIT :       Not Yet Assigned  
FOR :                    Novel Human Proteins and Polynucleotides Encoding Them

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to the examination of the above-referenced application, please amend the application as set forth below and consider the following remarks.

In the Drawings:

Replace the drawings in the application as filed with the enclosed drawings.

In the Specification:

Replace the title at page 1, line 1, with the following:

-- Novel Ig Superfamily Cell Surface Receptor-like Proteins and  
Polynucleotides Encoding Them --

Replace the text at page 1, lines 2-5, with the following text:

**--CONTINUATION DATA**

This application claims priority to USSN 09/544,511 filed April 6, 2000, pending, which claims the benefit of USSN 60/186,592 filed March 3, 2000, abandoned, and USSN 60/128,514 filed April 9, 1999, abandoned.--

Replace the text at page 109, lines 1-6, with the following text:

**--ABSTRACT**

This application is drawn to novel, isolated nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to human "200 gene" and human Ig superfamily cell surface receptor protein, as well as processes for preparing the same. The nucleotide sequence is 1203 nucleotides long and has an open reading frame from nucleotides 587 to 1013-1015 that encodes a polypeptide of 142 amino acids in length. The encoded polypeptides are novel proteins.--

**In the Claims:**

Cancel all the pending claims and add the following new claims

- 72. An isolated nucleic acid comprising any one of the following:
- (a) a nucleic acid sequence encoding a polypeptide of SEQ ID NO: 22;
  - (b) a nucleic acid sequence at least 90% identical to the nucleic acid sequence of (a) above;
  - (c) a nucleic acid encoding a polypeptide wherein the polypeptide has conservative amino acid substitutions to the polypeptide of SEQ ID NO: 22; or
  - (d) a fragment of the nucleic acid sequence of (a) or (b) above wherein the fragment comprises at least 20 nucleotides.

73. The nucleic acid of claim 72, wherein said nucleic acid is selected from the group consisting of DNA and RNA.
74. The nucleic acid of claim 72, wherein said nucleic acid comprises an open reading frame that encodes a polypeptide of SEQ ID NO: 22 or its complement, or a mutant or variant thereof.
75. The nucleic acid of claim 72 wherein said nucleic acid encodes a polypeptide comprising an amino acid of SEQ ID NO: 22 or its complement.
76. The nucleic acid of claim 74 wherein the nucleic acid encodes a mature form of a polypeptide comprising an amino acid sequence that is SEQ ID NO: 22.
77. The nucleic acid of claim 75 wherein said nucleic acid encodes a polypeptide comprising an amino acid of SEQ ID NO: 22, a mutant or variant thereof.
78. An oligonucleotide sequence that is complementary to and hybridizes under stringent conditions with the nucleic acid of claim 72, a variant or mutant thereof.
79. The oligonucleotide sequence of claim 78 which is complementary to at least a portion of the nucleotide sequence of SEQ ID NO: 21, its complement, or a mutant or variant thereof.
80. An isolated nucleic acid comprising a nucleotide sequence complementary to at least a portion of a nucleic acid according to claim 74.
81. A vector comprising the nucleic acid of claim 72.
82. A cell comprising the vector of claim 81.

83. The cell of claim 82 wherein said cell is a prokaryotic or eukaryotic cell comprising the nucleic acid sequence which is SEQ ID NO: 21, its complement, or a mutant or variant thereof.
84. A pharmaceutical composition comprising the nucleic acid of claim 72 and a pharmaceutically acceptable carrier.
85. A process for producing a polypeptide encoded by the nucleic acid of claim 72, said process comprising:
- a) providing the cell of claim 82;
  - b) culturing said cell under conditions sufficient to express said polypeptide; and
  - c) recovering said polypeptide,
- thereby producing said polypeptide.
86. The process of claim 85 wherein said cell is a prokaryotic or eukaryotic cell.
87. A process for identifying a compound that binds the nucleic acid of claim 72, the process comprising:
- a) contacting said nucleic acid with a compound; and
  - b) determining whether said compound binds said nucleic acid sequence.
88. The compound identified by the process of claim 87.--


**REMARKS**

Upon entry of the amendment, claims 72-88 will be pending in the application. Claims 1-71 are cancelled without prejudice to pursuing the subject matter of the cancelled claims in a continuing application. The title and abstract have been amended to reflect the subject matter now claimed. Support for the amendment to the title and abstract appears in, e.g., page 17, lines 11-17. Support for new claims 72-88 appears in at least the claims as filed. No new matter is added.

The Commissioner is authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 15966-546CON-S22. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Dated: September 26, 2001

  
Ivor R. Elrifi, Reg. No. 39,529  
Naomi S. Biswas, Reg. No. 38,384  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241